Endogenous insulin production is preserved in Type 1 diabetes with anti-TNF drug

Status
Not open for further replies.

Northerner

Admin (Retired)
Relationship to Diabetes
Type 1
In research led by a University at Buffalo pediatric endocrinologist, a drug called golimumab showed that it preserved beta-cell function in children and young adults with newly diagnosed Type 1 diabetes, according to findings from a Phase 2 study.

The study also demonstrated that golimumab, an anti-tumor-necrosis-factor (TNF) therapy, reduced the amount of injected insulin required by children and young adults with newly diagnosed Type 1 diabetes by preserving their ability to produce insulin on their own, called endogenous insulin. The World Without Disease Accelerator, through Janssen Research & Development, LLC, funded the study.

Golimumab, marketed as Simponi®, is currently used in the treatment of rheumatoid arthritis, ulcerative colitis and other autoimmune conditions, however it is not approved by the U.S. Food and Drug Administration for the treatment of Type 1 diabetes.

 
Golimumab has a terrifying list of potential side effects. It’s used occasionally in Ulcerative Colitis, in which I have an interest. Because of the potential for seriously unwanted side effects, it’s very much a last resort. The side effects are a result of what it is - it’s not a drug, it’s a monoclonal antibody, given by injection.

I don’t think it’s worth the risk in young T1s just to reduce the amount of insulin used.

In any event, I seriously mistrust reports funded by the company who makes the drug being assessed. Past experience shows that adverse effects tend to be under reported in that scenario, or even suppressed.
 
Status
Not open for further replies.
Back
Top